Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry.
Bruno VincenziAlessio CortelliniAlessandro MazzoccaSarah OrlandoDavide RomandiniJuan AguilarIsabel Ruiz-CampsClaudia Valverde MoralesSimeon Eremiev-EremievCarlo TondiniJoan BrunetRossella BertulliSalvatore ProvenzanoMark BowerDaniele GeneraliRamon SalazarAnna SuredaAleix PratMichalarea VasilikiMieke Van HemelrijckAilsa Sita-LumsdenAlexia BertuzziSabrina RossiAmanda JacksonFederica GrossoAlvin J X LeeCian MurphyKatherine BelessiotisUma MukherjeeFanny PommeretAngela LoizidouGianluca GaidanoGino M DettorreSalvatore GrisantiMarco TucciClaudia A M FulgenziAlessandra GennariAndrea NapolitanoDavid J PinatoPublished in: Therapeutic advances in medical oncology (2024)
In this study, we demonstrate an improvement in COVID-19 outcomes in patients with STS over time. Recent exposure to chemotherapy does not impact COVID-19 morbidity and mortality and SARS-CoV-2 vaccination confers protection against adverse outcomes from COVID-19 in this patient population.